Jean-Louis Peglion

USPTO Granted Patents = 52 (Patent Applications = 1)

CIPO Patents = 8

EPO Patents = 8 (Patent Applications = 9)

Average Co-Inventor Count = 4.2

ph-index = 8

Forward Citations = 286(Granted Patents)

Forward Citations (Not Self Cited) = 273(Oct 12, 2025)

Inventors with similar research interests:

Company Filing History:

Les Laboratoires Servier

patents

2 out of 5,069

Centre National De La Recherche Scientifique

patents

4. 2 out of 53

Les Laboratories Servier

patents

5. 1 out of 3

Les Laboratories Server

Universite Claude Bernard – Lyon1

patents

where one patent can have more than one assignee

Years Active: 1989-2017

Loading Chart...

52 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9809553 - Isoquinoline compounds, a process for their preparation, and pharmaceutical compositions containing them (2017-11-07),

2. 8476426 - Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid (2013-07-02),

3. 8415468 - Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid (2013-04-09),

4. 8288581 - Process for the preparation of functionalised benzocyclobutenes, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid (2012-10-16),

5. 8278440 - Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid (2012-10-02),

6. 8119794 - Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid (2012-02-21),

7. 8110701 - Process for the preparation of functionalised benzocyclobutenes, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid (2012-02-07),

8. 8101747 - Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid (2012-01-24),

9. 8097720 - Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid (2012-01-17),

10. 8076325 - 1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them (2011-12-13),

11. 7612061 - Piperazine compounds (2009-11-03),

12. 7470683 - Tetracyclic compounds (2008-12-30),

13. 7465733 - Piperazine compounds (2008-12-16),

14. 6908922 - Linear cyclic ureas (2005-06-21),

15. 6903103 - Linear cyclic ureas (2005-06-07),

Title: Jean-Louis Peglion: Innovating the Future of Medicinal Science

Introduction:

Meet Jean-Louis Peglion, a distinguished inventor and researcher hailing from Le Vesinet, France. With a remarkable portfolio of 52 patents, Jean-Louis has made significant contributions to the field of medicinal science. His latest patents focus on isoquinoline compounds and their pharmaceutical applications. In this article, we will delve into his impressive work, career highlights, collaborations, and the impact he has had on the industry.

Latest Patents:

Jean-Louis Peglion's most recent patents revolve around the development of isoquinoline compounds and their potential pharmaceutical applications. In particular, he has formulated compounds that are useful in treating or preventing pathologies resulting from the activation of the RhoA/ROCK pathway and phosphorylation of the myosin light chain. These inventions offer new possibilities for addressing critical health conditions by targeting specific cellular mechanisms.

Another key patent is pegged to the synthesis of ivabradine, a medication widely used to treat heart conditions. Jean-Louis has developed a highly efficient process for the synthesis of ivabradine and its addition salts with a pharmaceutically acceptable acid. This innovation opens doors for streamlined manufacturing and improved accessibility to this important cardiovascular drug.

Career Highlights:

Throughout his career, Jean-Louis Peglion has made significant contributions to renowned companies in the pharmaceutical industry. He has worked with Adir Et Compagnie, where he demonstrated his expertise in medicinal research and patent development. Furthermore, his association with Les Laboratoires Servier showcases his commitment to advancing the field of pharmaceutical sciences.

Collaborations:

Collaboration lies at the heart of scientific progress, and Jean-Louis understands the value of working with talented peers. He has collaborated with notable scientists like Mark Millan and Bertrand Goument, who share his passion for innovation and have collectively contributed to advancements in the pharmaceutical industry. These collaborations have fostered an environment of knowledge sharing and breakthrough discoveries.

Conclusion:

Jean-Louis Peglion's exceptional work and prolific patent portfolio have positioned him as an influential figure in the field of medicinal science. With a keen focus on isoquinoline compounds and innovative synthesis processes, his inventions have the potential to revolutionize the treatment of various pathologies. Through his career at esteemed companies such as Adir Et Compagnie and Les Laboratoires Servier, Jean-Louis has been instrumental in driving progress and pushing boundaries in the pharmaceutical industry. Collaborations with esteemed scientists like Mark Millan and Bertrand Goument further underline his commitment to collective innovation. As we anticipate future breakthroughs, Jean-Louis Peglion's contributions remain integral to paving the way for innovative solutions in medicine.

This text is generated by artificial intelligence and may not be accurate.